Insulin glargine
Dosing in kidney impairment
Renal Impairment The effect of renal impairment on the pharmacokinetics of BASAGLAR has not been studied. Some studies with human insulin have shown increased circulating levels of insulin in patients with renal failure. Frequent glucose monitoring and dose adjustment may be necessary for BASAGLAR in patients with renal impairment [see Warnings and Precautions] .
Dosing in liver impairment
Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of BASAGLAR has not been studied. However, as with all insulin products, more frequent glucose monitoring and dose adjustment may be necessary for BASAGLAR in patients with hepatic impairment [see Warnings and Precautions] .
Preparation and administration
Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions] . Visually inspect BASAGLAR prefilled pens for particulate matter and discoloration prior to administration. Only use if the solution is clear and colorless with no visible particles. Administer BASAGLAR subcutaneously into the abdominal area, thigh, or deltoid, and rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.
Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions and Adverse Reactions] . During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions] . Use BASAGLAR with caution in patients with visual impairment that may rely on audible clicks to dial their dose.
Do not dilute or mix BASAGLAR with any other insulin or solution. Do not administer intravenously or via an insulin pump.